Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Depletion of B lineage cells, including plasma cells, is a promising therapeutic strategy for immune-mediated diseases but can potentially reduce humoral immunity. Felzartamab, a fully human anti-CD38 monoclonal antibody targeting CD38+ plasmablasts and plasma cells, is under investigation in multiple immune-mediated diseases including immunoglobulin A nephropathy (IgAN) and primary membranous nephropathy (PMN). Results in PMN demonstrated preservation of vaccine immunity among felzartamab-treated patients. This analysis examined humoral responses in felzartamab-treated patients with IgAN.
In the Phase 2 IGNAZ study (NCT05065970), 48 patients with IgAN were randomized 1:1:1:1 in Part 1 to placebo or intravenous felzartamab (2 doses in 15 days, 5 doses in 2 months, or 9 doses in 5 months). In Part 2, 6 Japanese patients received the open-label 9-dose regimen. Serum samples were collected during on- and off-treatment periods and assessed using the Elecsys® Anti-SARS-CoV-2 S Assay (Roche Diagnostics) and VaccZyme™ Anti-Tetanus Toxoid (TT) IgG Enzyme Immunoassay (MK010).
Of 54 patients enrolled, 46/53 with available data had protective anti-TT titers at baseline and 45/48 had positive anti-SARS-CoV-2 titers. Baseline anti-TT immunity was maintained throughout the study; 4 patients (1 placebo) decreased to below protective titer (<0.1 U/mL) during the study; however, all had low baseline titers and reductions were minimal with titers staying >0.08 U/mL. Similarly, patients maintained positive baseline titers of anti-SARS-CoV-2 during the study. Across arms, 16 patients received ≥1 SARS-CoV-2 vaccination on study and 17 patients experienced acute SARS-CoV-2 infections. Seven of 8 patients with data pre- and post-vaccination mounted a vaccine response regardless of treatment arm. Similarly, 5/6 patients generated antibody responses to SARS-CoV-2 infection while receiving treatment.
Patients with IgAN receiving felzartamab demonstrated preservation of humoral immunity, which may contribute to a favorable safety profile versus other B-cell targeting therapies. These findings are consistent with those previously observed in PMN.
This abstract was also submitted for ASN Kidney Week 2025 congress.
